MedTrace Logo

Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept

NCT03715127 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2022-04-29

No results posted yet for this study

Summary

Effects of serotonin 2A/1A receptor stimulation by psilocybin on mood and emotion processing in major depressive disorder: a randomized double-blind placebo-controlled study

Conditions

  • Depressive Disorder, Major

Interventions

DRUG

Psilocybine oral capsule

single dose of psilocybin (0.215mg / kg body weight)

DRUG

Placebo oral capsule

single dose of placebo (100% mannitol)

Sponsors & Collaborators

  • Schweizerischer Nationalfonds

    collaborator OTHER

  • University of Zurich

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-11
Primary Completion
2021-10-12
Completion
2022-04-12

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03715127 on ClinicalTrials.gov